Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : How To Write Covered Calls - An Ongoing Real Case Study! -- Ignore unavailable to you. Want to Upgrade?

To: Herm who wrote (7336)	4/23/1998 4:13:00 PM
From: drsvelte	Read Replies (1) \| Respond to of 14162

Herm -- this one's for you! from Briefing.com Vivus Inc. (VVUS) 12 5/16 +4 5/16: Cruttenden Roth upgrades erectile dysfunction treatment concern from "neutral" to "strong buy" on view that sales of Muse should benefit from greater public awareness of male problem and competitor's Viagra oral drug; also thinks that Muse may be more beneficial in mild to moderate cases......

To: Herm who wrote (7336)	4/23/1998 4:47:00 PM
From: rkf	Read Replies (1) \| Respond to of 14162

Herm, what's your bottom line take on VVUS right now. The fundamental issue with me always gets back to - does Muse work?. I'm holding tight with what I've got right now, my net basis is $21. Does the class action suit mean much of anything to you - or is this typical? Kent